OCT-1 Expression in Patients with Chronic Myeloid Leukemia: A Comparative Analysis with Respect to Response to Imatinib Treatment

This study was conducted on 101 patients with CML [imatinib sensitive (n  = 51) and imatinib resistant (n = 50)] who were treated with imatinib. Gene expression analysis was done using QRT-PCR. The relative expression levels ofOCT-1 were calculated using 2( −ΔΔCT) method.OCT1 mRNA expression levels were 0.149 (0.011 –2.532) and 0.119 (0.008–2.868) in imatinib-sensitive group and imatinib-resistant group, respectively.OCT-1 expression levels were not significantly different in the imatinib-sensitive group when compared to imatinib resistant group (p >  0.05).OCT-1 expression was also similar inBCR-ABL1 kinase domain mutation positive and negative cases (p >  0.05). The imatinib-resistant group had a higher rate of hydroxyurea or interferon-alpha treatment prior to imatinib therapy and a lower rate for first-line imatinib as the only treatment than the imatinib-sensitive group (p = 0.002 andp = 0.002, respectively). According to the results of our study,OCT-1 does not have a biomarker feature in the evaluation of imatinib response. In addition, the study should be performed in larger patient groups.
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research